RCT 18

Drug Profile

RCT 18

Alternative Names: RC18; Tai’ai

Latest Information Update: 13 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yantai Rongchang Biological Engineering
  • Class Fibroblast cell therapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 01 Sep 2016 Phase-III clinical trials in Rheumatoid arthritis (Adjunctive treatment) in China (SC) (NCT03016013)
  • 30 Aug 2016 Phase-II clinical trials in Systemic lupus erythematosus in China (SC) (NCT02885610)
  • 04 Dec 2015 Pharmacokinetics and immunogenecity data from a phase I trial in Systemic lupus erythematosus released in December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top